Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis

On May 29, 2026, the FDA approved ensitrelvir fumaric acid (Xocova) for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual who has COVID-19. Xocova is the first and only oral antiviral approved in the United States to prevent COVID-19 after exposure — filling a gap that Paxlovid (nirmatrelvir/ritonavir) could not address, since Paxlovid failed to demonstrate post-exposure prophylaxis efficacy in its EPIC-PEP trial.

This access guide is for infectious disease pharmacists, antimicrobial stewardship teams, payer medical directors, and health-system pharmacy leaders who need to understand Xocova's regulatory status, clinical evidence, dosing, prior authorization requirements, and payer positioning.

What Xocova is and how it works

Xocova (ensitrelvir fumaric acid) is a SARS-CoV-2 main protease (3CL protease) inhibitor developed through joint research between Hokkaido University and Shionogi. It blocks the 3CL enzyme that SARS-CoV-2 needs to replicate, preventing the virus from making copies of itself after exposure.

Key parameters:

Unlike Paxlovid, Xocova does not contain ritonavir and does not require pharmacokinetic boosting. This means it avoids the extensive cytochrome P450 3A4 drug–drug interaction profile that limits Paxlovid use in patients on statins, antiplatelet agents, immunosuppressants, and other commonly co-prescribed medications. However, Xocova does have some drug interaction considerations — prescribers should consult the full prescribing information for contraindicated and interacting medications.

Xocova has been approved in Japan since 2022 (first under emergency authorization, then full approval in March 2024) for the treatment of COVID-19. It is also available in Singapore. The US approval covers the prophylaxis indication.

Importantly, the PROTECT-HD study presented at the ISN World Congress of Nephrology 2026 demonstrated that ensitrelvir exposure and pharmacokinetics were not affected by hemodialysis, and the drug was associated with favorable clinical responses in patients on dialysis without dose adjustment. This makes Xocova a potentially important option for patients with end-stage renal disease, a population at high risk for severe COVID-19.

SCORPIO-PEP: the pivotal phase 3 trial

The FDA approval was based on the SCORPIO-PEP trial (NCT05897541), a global, double-blind, randomized, placebo-controlled phase 3 study published in the New England Journal of Medicine on May 13, 2026.

Key design and findings:

• Population: Nearly 2,400 participants aged 12 and older across the United States, Argentina, Japan, South Africa, and Vietnam. All were household contacts of someone with confirmed COVID-19 (positive test with at least one symptom). Participants were enrolled within 72 hours of symptom onset in the index patient.
• Intervention: Ensitrelvir once daily for 5 days versus placebo
• Primary endpoint: The trial met its primary endpoint. Ensitrelvir significantly reduced the risk of developing symptomatic COVID-19 by day 10 compared with placebo.
• Meta-analysis: A real-time meta-analysis of prophylaxis studies showed a pooled relative risk of 0.32 (95% CI 0.22–0.48, p < 0.0001) for symptomatic COVID-19 with ensitrelvir PEP versus placebo.
• Safety: Ensitrelvir was generally well tolerated in the trial. Adverse events were mild to moderate and consistent with the known safety profile established in the Japanese treatment program.
• Complementary to vaccination: Most participants had some prior immunity. Study co-author Paul E. Sax noted that ensitrelvir PEP is "complementary to vaccination rather than replacing it."

The context is important: up to 47% of people who live with someone infected with COVID-19 may develop it themselves. The CDC estimated 3.8 million to 12.4 million new COVID cases in the US from October 2025 through May 23, 2026, leading to hundreds of thousands of outpatient visits, approximately 240,000 hospitalizations, and 13,000 to 42,000 deaths.

Why this matters: the Paxlovid PEP failure

The FDA's approval of Xocova for PEP is significant because Paxlovid — the dominant oral COVID antiviral — failed in its own post-exposure prophylaxis trial (EPIC-PEP), published in NEJM in 2024. In that trial, nirmatrelvir-ritonavir did not significantly reduce the risk of symptomatic COVID-19 in exposed household contacts.

Until now, the only FDA-authorized preventive options for COVID-19 were pre-exposure: monoclonal antibodies (most of which have lost EUA authorization due to variant escape) and vaccines. Xocova fills a specific need: oral prevention after a known exposure, before symptoms develop.

Access implications for payers and health systems

Formulary positioning

Xocova will enter a category that has changed significantly since the peak of the pandemic. Paxlovid transitioned from government-purchased distribution to commercial market access in late 2024. Oral antivirals for COVID-19 are now managed through standard pharmacy benefit channels.

Expected formulary considerations:

• Prior authorization likely at launch for most commercial and Medicare Part D plans, requiring documented household or close-contact exposure to a confirmed COVID-19 case
• Step therapy is unlikely given Xocova is the only oral PEP; Paxlovid does not have a PEP indication
• Age restriction: approved for ages 12 and older; pediatric formulations or younger age groups are not covered
• Stewardship: Infectious disease and pharmacy benefit teams should develop criteria ensuring Xocova is prescribed within the approved window (within 72 hours of exposure)

Payer and benefit design

Because Xocova is an oral medication, it will be adjudicated under the pharmacy benefit:

• Pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) will manage prior authorization rather than medical benefit utilization management teams
• Retail pharmacy distribution is expected given the oral formulation and 5-day course
• Timing-sensitive access is critical — the drug must be started soon after exposure to be effective, which means PA turnaround and real-time benefit checks need to be fast
• Medicare Part D coverage will follow standard Part D formulary placement; Xocova's COVID-19 indication may receive favorable tiering given its prevention focus

Comparison with Paxlovid positioning

The two drugs serve different populations: Xocova for prevention after exposure, Paxlovid for treatment after infection. They are complementary, not competitive.

Pricing and affordability

Shionogi has not yet disclosed US pricing for Xocova at the time of approval. Paxlovid's commercial price is approximately $1,400 per course, which serves as a reference point.

Factors that will influence Xocova pricing:

• The prevention indication may support premium pricing given the potential to avoid COVID-19 infection, medical visits, and lost productivity
• The 5-day oral course and lack of drug–drug interaction burden could support a value argument versus Paxlovid's limitations
• Shionogi may offer patient savings programs or manufacturer copay cards at launch
• Government purchasing or stockpiling arrangements are possible given the ongoing public health relevance of COVID-19 countermeasures

Antimicrobial stewardship considerations

The infectious disease community has raised several points about Xocova's stewardship:

• Appropriate use criteria: Stewardship programs should develop guidelines for when Xocova PEP is appropriate — particularly for household contacts of confirmed cases, outbreak settings (nursing homes, long-term care facilities), and immunocompromised individuals
• Resistance monitoring: 3CL protease inhibitor resistance has been observed in vitro; ongoing surveillance is needed as use scales
• Diagnostic requirement: Whether payers will require a confirmed positive test in the index patient before approving Xocova PEP
• Outbreak settings: Xocova could be particularly valuable in congregate care settings (nursing homes, acute care facilities) where COVID-19 outbreaks pose high risk to vulnerable populations

What to watch

• Shionogi US launch: Pricing announcement, distribution network, and patient support program details
• PBM formulary decisions: Watch CVS Caremark, Express Scripts, and OptumRx for formulary positioning and PA criteria in 2026 updates
• ACIP or CDC guidance: Whether the CDC updates COVID-19 treatment and prevention guidance to include ensitrelvir PEP
• Expanded indications: Shionogi may seek a treatment indication for Xocova in the US (already approved for treatment in Japan)
• Pediatric expansion: Whether Shionogi pursues studies in children under 12
• Real-world effectiveness data: Post-marketing studies will be important to confirm SCORPIO-PEP results in routine clinical practice
• Resistance surveillance: SARS-CoV-2 3CL protease mutation monitoring as Xocova use scales

Sources

• FDA. "Novel Drug Approvals for 2026." Updated June 1, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• Shionogi Inc. "FDA Accepts Shionogi's Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure." September 2, 2025. https://www.shionogi.com/us/en/news/2025/09/fda-accepts-shionogis-ensitrelvir-nda-as-the-first-oral-therapy-for-the-prevention-of-covid-19-following-exposure.html
• Hayden FG, Shinkai M, et al. "Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts." New England Journal of Medicine 2026;394(19):1905-1915. doi:10.1056/NEJMoa2509306
• Shionogi & Co. "Shionogi Announces FDA Approval of XOCOVA (ensitrelvir)." June 1, 2026. https://www.shionogi.com/global/en/news/2026/06/20260601.html
• ClinicalTrials.gov. "SCORPIO-PEP: Ensitrelvir for Post-Exposure Prophylaxis of COVID-19." NCT05897541. https://clinicaltrials.gov/ct2/show/NCT05897541
• Fierce Pharma. "Shionogi's COVID Antiviral Xocova Passes Muster with FDA as Post-Exposure Preventative." June 1, 2026. https://www.fiercepharma.com/pharma/shionogis-covid-antiviral-xocova-passes-muster-fda-post-exposure-preventative
• Medscape. "Ensitrelvir Earns Approval for Postexposure COVID Protection." June 2026. https://www.medscape.com/viewarticle/ensitrelvir-earns-approval-postexposure-covid-protection-2026a1000i9h
• Drugs.com. "Ensitrelvir FDA Approval Status." Updated 2026. https://www.drugs.com/history/ensitrelvir.html